Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company’s Board of Directors
March 18 2021 - 8:30AM
Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics,
Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the
"
Company" or "
Claritas") today
announced that Robert Farrell, J.D., the Company’s President and
CEO has been appointed Chairman of the Company’s board of directors
(the “Board of Directors”), effective immediately.
The Company also announced the resignations of
current independent board members Mr. Robin (“Rob”) Hutchison and
Ronald Erickson, J.D., effective immediately. The resignations of
Mr. Hutchison and Mr. Erickson follows the recent appointment of
Professor Salvatore Cuzzocrea, Ph.D. to the Company’s Board of
Directors. Prof. Cuzzocrea is an independent board member, and is
an acknowledged expert in the science of nitric oxide therapy.
"I want to extend my gratitude to Rob Hutchison
and Ron Erickson for their distinguished service and contributions
to our Board of Directors,” stated Mr. Farrell. “Both Rob and Ron
have been integral members of our Board of Directors, and we wish
them all the best going forward.”
“We are assembling a world-class team of experts
in the science and clinical use of nitric oxide, at management,
advisory and board levels within the Company,” stated Farrell. “We
recently announced the addition of Prof. Salvatore Cuzzocrea to our
board of directors, and the addition of Dr. Garry Southan to our
Scientific Advisory Board. Prof. Cuzzocrea and Dr. Southan are each
world-renowned experts in the science of nitric oxide. Our
proprietary new drug, R-107, is a liquid, nitric oxide releasing
molecule that could transform nitric oxide therapy from a difficult
to use inhalational therapy to a pharmaceutical that can be
administered orally by capsule or by injection. R-107 is a platform
technology that is designed to unleash the potential of nitric
oxide as a practical out-patient therapy for many diseases and
disorders. With R-107, we will position Claritas as the world’s
leader in nitric oxide pharmacology.”
About Claritas
PharmaceuticalsClaritas Pharmaceuticals, Inc. is a
clinical stage biopharmaceutical company focused on developing and
commercializing therapies for patients with significant unmet
medical needs. Claritas focuses on areas of unmet medical need, and
leverages its expertise to find solutions that will improve health
outcomes and dramatically improve people's lives.
- Website
Home: https://claritaspharma.com/
- News and
Insights: https://claritaspharma.com/news/
-
Investors: https://claritaspharma.com/investors
Cautionary StatementsNeither
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
This press release may contain certain
forward-looking information and statements ("forward-looking
information") within the meaning of applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation in respect of its product candidate pipeline,
planned clinical trials, regulatory approval prospects,
intellectual property objectives, and other statements containing
the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects", "continue", "estimate", "forecasts" and other
similar expressions. Readers are cautioned to not place undue
reliance on forward-looking information. Actual results and
developments may differ materially from those contemplated by these
statements depending on, among other things, the risk that future
clinical studies may not proceed as expected or may produce
unfavorable results. Claritas undertakes no obligation to comment
on analyses, expectations or statements made by third parties, its
securities, or financial or operating results (as applicable).
Although Claritas believes that the expectations reflected in
forward-looking information in this press release are reasonable,
such forward-looking information has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Claritas’ control. The forward-looking
information contained in this press release is expressly qualified
by this cautionary statement and is made as of the date hereof.
Claritas disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise.
Contact InformationRobert
FarrellPresident, CEO(888) 861-2008info@claritaspharma.com
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From Apr 2024 to May 2024
Kalytera Therapeutics (TSXV:KLY)
Historical Stock Chart
From May 2023 to May 2024